Skip to main content

COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals

Journal: Vaccine
Lead Author: KFaksova et al
Original date of publication: 02/12/2024
Link: https://pubmed.ncbi.nlm.nih.gov/38350768/

Summary Context

Expansive study of over 99 million people in Vaccine, which analyzes the outcomes for those who took mRNA and viral vector injections, and confirms well-known side effects of note, and identifies new adverse events for further investigation.

Comments

This article is copyrighted by Health Freedom Defense Fund, Inc.
Visit our Re-post guidelines

This study showed that the adverse events of concern were clearly a replicable issue– drawing on this registry of 99 million recipients. It also identified worrying new conditions and reactions for further investigation. Study is somewhat impacted by relatively small number of recipients who received the ChAdOx1 (Oxford) vaccine that is not an mRNA platform. Some notable statistics: Roughly 6x rates of myocarditis following injection, almost 4x rates of acute disseminated encephalomyelitis. Almost 2.5x the rate of Guillain-Barre syndrome (GBS) and 3x rate of cerebral thrombosis (CVST) after the Oxford injection.

Abstract or Results, Key Passages

“The Global COVID Vaccine Safety (GCoVS) Project, established in 2021 under the multinational Global Vaccine Data Network™ (GVDN®), facilitates comprehensive assessment of vaccine safety. This study aimed to evaluate the risk of adverse events of special interest (AESI) following COVID-19 vaccination from 10 sites across eight countries. Results: This multi-country analysis confirmed pre-established safety signals for myocarditis, pericarditis, Guillain-Barré syndrome, and cerebral venous sinus thrombosis. Other potential safety signals that require further investigation were identified.”

Keywords: adverse eventscovid vaccinationGuillain-Barre syndromemyocarditispericarditisthrombosis
Full Author List: K Faksova, D Walsh, Y Jiang, J Griffin, A Phillips, A Gentile, J C Kwong, K Macartney, M Naus, Z Grange, S Escolano, G Sepulveda, A Shetty, A Pillsbury, C Sullivan, Z Naveed, N Z Janjua, N Giglio, J Perälä, S Nasreen, H Gidding, P Hovi, T Vo, F Cui, L Den, L Cullen, M Artama, H Lu, H J Clothier, K Batty, J Paynter, H Petousis-Harris, J Buttery, S Black, A Hviid